Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-arm, multicenter, phase III study to investigate the efficacy and safety of rituximab in Japanese patients with chronic immune thrombocytopenia.

Trial Profile

A single-arm, multicenter, phase III study to investigate the efficacy and safety of rituximab in Japanese patients with chronic immune thrombocytopenia.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 May 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary)
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 May 2014 New trial record
    • 10 Dec 2013 The primary endpoint of "platelet count" has been met according to results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top